Publication
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors.
Authors not recorded
Biomark Res2020PMID 33298164PMC7724704stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Neoplasmcivic_curation1.00
- drugImmunotherapycivic_curation1.00
- geneKMT2Acivic_curation1.00
- geneKMT2Ccivic_curation1.00
- variantKMT2A Mutationcivic_curation1.00
- variantKMT2C Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33298164
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KMT2A Mutation + KMT2C MutationKMT2CKMT2A1 | ||||||||
| Immunotherapy | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12031This study examined the role of KMT2A/C mutations as a potential biomarker for predicting the effectiveness of immunotherapy. In the primary ICI-treated cohort (n = 546), the researchers observed that… (full text at CIViC) PMID 33298164 · Zhang et al., 2020 · Open in CIViC | civic |